NASDAQ: BLRX
Biolinerx Ltd Stock Forecast, Predictions & Price Target

Analyst price target for BLRX

Based on 2 analysts offering 12 month price targets for Biolinerx Ltd

Min Forecast
$12.00+155.86%
Avg Forecast
$19.00+305.12%
Max Forecast
$26.00+454.37%

Should I buy or sell BLRX stock?

Based on 2 analysts offering ratings for Biolinerx Ltd.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their BLRX stock forecasts and price targets.

BLRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-05-30
lockedlocked$00.00+00.00%2025-05-28

1 of 1

Forecast return on equity

Is BLRX forecast to generate an efficient return?

Company
0%
Industry
83.55%
Market
67.39%
BLRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BLRX forecast to generate an efficient return on assets?

Company
0%
Industry
22.55%
BLRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BLRX earnings per share forecast

What is BLRX's earnings per share in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$0.08
Avg 2 year Forecast
$0.00
Avg 3 year Forecast
$0.00

BLRX revenue forecast

What is BLRX's revenue in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
$2.2M-90.02%
Avg 2 year Forecast
$7.7M-65.58%
Avg 3 year Forecast
$12.8M-42.93%
BLRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BLRX revenue growth forecast

How is BLRX forecast to perform vs Biotechnology companies and vs the US market?

Company
-41.89%
Industry
130.42%
Market
9.85%
BLRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BLRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BLRX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
BLRX$4.69$19.00+305.12%Strong Buy
SLGL$7.52N/AN/A
IMNN$1.43$15.50+983.92%Strong Buy
BIVI$1.14N/AN/A
LSTA$2.50N/AN/A

Biolinerx Stock Forecast FAQ

Is Biolinerx Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: BLRX) stock is to Strong Buy BLRX stock.

Out of 2 analysts, 1 (50%) are recommending BLRX as a Strong Buy, 1 (50%) are recommending BLRX as a Buy, 0 (0%) are recommending BLRX as a Hold, 0 (0%) are recommending BLRX as a Sell, and 0 (0%) are recommending BLRX as a Strong Sell.

If you're new to stock investing, here's how to buy Biolinerx stock.

What is BLRX's earnings growth forecast for 2025-2027?

(NASDAQ: BLRX) Biolinerx's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 12.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 19.71%.

Biolinerx's earnings in 2025 is -$3,398,000.On average, 1 Wall Street analyst forecast BLRX's earnings for 2025 to be $178,608,159, with the lowest BLRX earnings forecast at $178,608,159, and the highest BLRX earnings forecast at $178,608,159. On average, 1 Wall Street analyst forecast BLRX's earnings for 2026 to be $0, with the lowest BLRX earnings forecast at $0, and the highest BLRX earnings forecast at $0.

In 2027, BLRX is forecast to generate $0 in earnings, with the lowest earnings forecast at $0 and the highest earnings forecast at $0.

What is BLRX's revenue growth forecast for 2025-2027?

(NASDAQ: BLRX) Biolinerx's forecast annual revenue growth rate of -41.89% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 130.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.85%.

Biolinerx's revenue in 2025 is $22,340,000.On average, 2 Wall Street analysts forecast BLRX's revenue for 2025 to be $4,978,702,438, with the lowest BLRX revenue forecast at $3,706,119,303, and the highest BLRX revenue forecast at $6,251,285,572. On average, 1 Wall Street analysts forecast BLRX's revenue for 2026 to be $17,168,709,303, with the lowest BLRX revenue forecast at $17,168,709,303, and the highest BLRX revenue forecast at $17,168,709,303.

In 2027, BLRX is forecast to generate $28,465,675,373 in revenue, with the lowest revenue forecast at $28,465,675,373 and the highest revenue forecast at $28,465,675,373.

What is BLRX's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: BLRX) forecast ROA is 0%, which is lower than the forecast US Biotechnology industry average of 22.55%.

What is BLRX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year BLRX price target, the average BLRX price target is $19.00, with the highest BLRX stock price forecast at $26.00 and the lowest BLRX stock price forecast at $12.00.

On average, Wall Street analysts predict that Biolinerx's share price could reach $19.00 by May 30, 2026. The average Biolinerx stock price prediction forecasts a potential upside of 305.12% from the current BLRX share price of $4.69.

What is BLRX's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BLRX) Biolinerx's current Earnings Per Share (EPS) is $0.00. On average, analysts forecast that BLRX's EPS will be $0.08 for 2025, with the lowest EPS forecast at $0.08, and the highest EPS forecast at $0.08. On average, analysts forecast that BLRX's EPS will be $0.00 for 2026, with the lowest EPS forecast at $0.00, and the highest EPS forecast at $0.00. In 2027, BLRX's EPS is forecast to hit $0.00 (min: $0.00, max: $0.00).

What is BLRX's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: BLRX) forecast ROE is 0%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.